Clinical trials: Envafolimab
Ovarian Cancer, Epithelial
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
This study is a single-arm, open-label, exploratory clinical study, the main purpose is to evaluate the combination of envafolimab, lenvatinib VP-16 in the treatment of platinum-resistant recurrent epithelial ovarian…
- Trial name
- NCT05422183
- Testing
- Envafolimab, Lenvatinib, VP-16
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Zhongda Hospital
Lung Neoplasms
Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC
To evaluate the efficacy and safety of envafolimab combined with endostar in the first-line treatment of advanced Non-small Cell Lung Cancer With PD-L1 positive expression
- Trial name
- NCT05203276
- Testing
- Envafolimab, Endostar
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The First People's Hospital of Lianyungang
Healthy Male
Phase I Trial of Envafolimab for Healthy Male Subjects
The purpose of this study is to evaluate the pharmacokinetic similarity, safety, and immunogenicity of Envafolimab in healthy male subjects before and after the manufacturing process change.
- Trial name
- NCT05849311
- Testing
- Envafolimab with new manufacturing process, Envafolimab with old manufacturing process
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Intrahepatic Cholangiocarcinoma
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.
- Trial name
- NCT06643208
- Testing
- TACE-HAIC, Envafolimab and Lenvatinib
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Fujian Provincial Hospital